Who owns Xbiotech?
- Ticker: XBIT
- CUSIP Number: 98400h102
Tip: Access positions for across all investors
Analyze quarterly positions in Xbiotech with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of Xbiotech stock
Who bought or sold Xbiotech this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
|---|---|---|---|---|---|
| Millennium Management | 927k | $7.5M | 17% | Mar 2024 |
|
| Vanguard Group | 895k | $7.3M | 2% | Mar 2024 |
|
| BlackRock | 307k | $2.5M | 10% | Mar 2024 |
|
| Credit Suisse | 248k | $2.0M | 0% | Mar 2024 |
|
| Geode Capital Management | 195k | $1.6M | 7% | Mar 2024 |
|
| Susquehanna International | 170k | $1.4M | 314% | Mar 2024 |
|
| Bridgeway Capital Management | 149k | $1.2M | 7% | Mar 2024 |
|
| Morgan Stanley | 116k | $946k | 33% | Mar 2024 |
|
| Connor, Clark & Lunn Investment Management | 77k | $629k | 21% | Mar 2024 |
|
| Northern Trust | 75k | $613k | 43% | Mar 2024 |
|
| Dimensional Fund Advisors | 73k | $589k | 0% | Mar 2024 |
|
| Qube Research & Technologies | 68k | $550k | 2543% | Mar 2024 |
|
| Empowered Funds | 64k | $523k | 19% | Mar 2024 |
|
| Goldman Sachs Group | 62k | $505k | 100% | Mar 2024 |
|
| Jane Street | 55k | $446k | 236% | Mar 2024 |
|
| Marshall Wace | 55k | $445k | 100% | Mar 2024 |
|
| Bank of New York Mellon | 49k | $394k | -13% | Mar 2024 |
|
| Citigroup | 37k | $299k | 149% | Mar 2024 |
|
| Hrt Financial | 34k | $273k | 100% | Mar 2024 |
|
| Point72 Asia | 26k | $211k | 100% | Mar 2024 |
|
| National Bank Of Canada /fi/ | 24k | $103k | 100% | Dec 2023 |
|
| Balyasny Asset Management | 22k | $178k | 100% | Mar 2024 |
|
| Brevan Howard Capital Management | 21k | $167k | 100% | Mar 2024 |
|
| FMR | 20k | $162k | 0% | Mar 2024 |
|
| Two Sigma Advisers | 18k | $150k | -23% | Mar 2024 |
|
| Y-Intercept | 18k | $147k | 100% | Mar 2024 |
|
| T. Rowe Price Associates | 18k | $144k | 0% | Mar 2024 |
|
| ExodusPoint Capital Management | 16k | $132k | 100% | Mar 2024 |
|
| Citadel Advisors | 15k | $122k | 13% | Mar 2024 |
|
| TNB Financial | 13k | $109k | 0% | Mar 2024 |
|
| Bnp Paribas Arbitrage, Snc | 13k | $102k | 11% | Mar 2024 |
|
| Two Sigma Investments | 11k | $87k | -58% | Mar 2024 |
|
| Charles Schwab Investment Management | 11k | $85k | 0% | Mar 2024 |
|
| Bank of America Corporation | 8.7k | $71k | -35% | Mar 2024 |
|
| UBS Group | 7.3k | $60k | -22% | Mar 2024 |
|
| Cubist Systematic Strategies | 5.3k | $43k | 100% | Mar 2024 |
|
| Tower Research Capital | 1.1k | $9.1k | 100% | Mar 2024 |
|
| Rhumbline Advisers | 753.00 | $6.1k | 0% | Mar 2024 |
|
| McIlrath & Eck | 753.00 | $6.1k | 0% | Mar 2024 |
|
| Simplex Trading | 228.00 | $1.0k | -64% | Mar 2024 |
|
| Wells Fargo & Company | 155.00 | $1.3k | 2% | Mar 2024 |
|
| Royal Bank of Canada | 99.00 | $999.999000 | -66% | Mar 2024 |
|
| Jpmorgan Chase & Co | 38.00 | $309.000800 | 0% | Mar 2024 |
|
Who sold out of Xbiotech?
| Fund or Company Name | Date Sold | Shares Held | Valued At |
|---|---|---|---|
| Man Group | Dec 2023 | 58k | $233k |
| Squarepoint Ops | Dec 2023 | 19k | $76k |
| LGT Fund Management | Dec 2023 | 10k | $40k |
| Group One Trading | Sep 2023 | 1.7k | $7.2k |